BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-24@pharmaconomics
DTSTAMP:20260707T034239Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRMY Phase 1 — OX2R (estimated date)
DESCRIPTION:Phase 1 trial results for OX2R in its lead indication are due ~ Dec 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1802665/000110465926002731/hrmy-20260112xex99d2.htm\n\nTrack it: https://www.pharmaconomics.com/e/24
URL:https://www.pharmaconomics.com/e/24
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:HRMY catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR